Yesterday physIQ announced that the it got the FDA nod for its latest product, an atrial fibrillation detection analytics engine designed to be used in both a patient care setting and in clinical trials. The system is intended to give further clinical insights about patients' atrial fibrillation, and will work with the company’s other products already approved to provide data analyses. 

“Since day one our mission has been to enable a world where real-time patient data continuously streams to the cloud and artificial intelligence performs the hard work of detecting when health problems are arising among monitored patients,” Gary Conkright, chairman and CEO of physIQ, said in a statement.  “With this approach, clinicians can identify who within their monitored population may require additional care to avoid poor health outcomes. This clearance of our [atrial fibrillation] detection algorithm, when paired with our groundbreaking and previously cleared personalized physiology analytics, is a huge step towards realizing that goal.

Following this announcement the technology will be available and integrated in physIQ’s patient care wearable pinpointIQ as well as accelerateIQ, a platform which is focused on clinical trials. pinpointIQ is a wearable biosensor that able to continuously capture data. It can also give personalized analytics to detect at-risk patients, according to the company’s webpage. The accelerateIQ platform is used for research and can capture data through biosensors, and then stream them to physIQ’s cloud platform. It can also quantify the impacts of clinical trials on patients.

This isn’t the first FDA clearance for PhysIQ. In 2015 the Chicago-based company landed a clearance for its physiology analytics system. 

Earlier this year the VA teamed up with the AI company to sponsor a study that deployed wearable biosensors to post-acute heart failure patients, and used the physIQ's analytics platform to detect vital sign anomalies. 

But most recently, VitalConnect and physIQ teamed up with Dutch provider Haga Teaching Hospital to conduct a study on how wearable biosensors and AI can augment care for cancer patients undergoing treatment. Specifically, the study — which is funded by Johnson & Johnson subsidiary Janssen Pharmaceuticals — was set up to look at how the technology can detect adverse events in cancer treatment early on. 

“Once a patient leaves the hospital, a clinician’s ability to track his/her progress traditionally has been limited, which is why we historically have seen high readmission rates,” Dr. Steven Steinhubl of the Scripps Translational Science Institute, said in a statement.  “This FDA clearance is another example of how physIQ’s AI expertise is ushering in an era where advanced personalized physiology analytics applied to continuous biosensor data can give clinicians the insight they need to drive down rehospitalizations and accelerate our pace towards personalized precision medicine.”